The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
Phase of Trial: Phase II
Latest Information Update: 01 May 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ATTAIN
- 18 Aug 2017 Status changed from active, no longer recruiting to discontinued due to poor accrual.
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2015 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019 as reported by ClinicalTrials.gov.